


revenue growth.

C-Path Announces Steven W. Spector and James A. King as New Board Members

TUCSON, Ariz., March 06, 2025 — Critical Path Institute® (C-Path) today announced the appointments of Steven W. Spector and James A. King to its Board of Directors, as the organization continues to lead and innovate in the field of drug development and regulatory science.

With over 20 years of senior executive experience in the biopharmaceutical industry, Steven W. Spector has managed a broad array of corporate functions including legal, business development, compliance, and government relations. He served as Executive Vice President, Head of Business Development, and General Counsel at Longboard Pharmaceuticals, Inc. During his tenure at Longboard Pharmaceuticals, from its inception until its acquisition by H. Lundbeck A/S in December 2024, Spector was instrumental in navigating the company through critical stages of development and the significant expansion of its drug pipeline. Previously, Mr. Spector held various executive roles at Arena Pharmaceuticals, Inc., helping to steer the company through development and regulatory challenges until its acquisition by Pfizer Inc.







"Welcoming Steven Spector and James King to our board represents a strategic evolution at C-Path, designed to harness their exceptional expertise at a crucial time in our history," said Wainwright Fishburn, Chairman of the Board at C-Path. "Their leadership in navigating significant corporate and technological transformations aligns perfectly with our mission to innovate drug development. This move is a clear signal of C-Path's dedication to shaping a future where patient care benefits from the most advanced scientific knowledge and collaboration."

"We are very excited to welcome Steven and Jim to our board," said C-Path CEO Klaus Romero, M.D., M.S., FCP. "Their combined expertise in biopharmaceuticals and technology, along with their proven track records of leadership in complex corporate environments, makes them invaluable additions to the team. Their vast and diverse experience will be critical as we continue to develop and implement innovative solutions

that advance patient care and improve drug development."

The appointments of Mr. Spector and Mr. King are effective immediately. They will bring their strategic perspectives to bear in supporting C-Path's mission, further strengthening the Institute's position as the leader in transforming global health outcomes.

About Critical Path Institute

Founded in 2005, as a public-private partnership in response to the <u>FDA's Critical Path Initiative</u>, Critical Path Institute® (C-Path) celebrates its 20th anniversary as a vital, independent, nonprofit. **C-Path's mission is to lead collaborations that advance better treatments for people worldwide**. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path's global headquarters is located in Tucson, Arizona and C-Path's Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit <u>c-path.org</u>.

Media Contacts:

Roxan Triolo Olivas C-Path 520.954.1634 rolivas@c-path.org

Kissy Black C-Path 615.310.1894 kblack@c-path.org